NCT06418529

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Name: Clinical Trial NCT06418529
Creator: Pfizer
Keywords: Rheumatoid Arthritis, tofacitinib, drug, clinical trial

Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid Arthritis

Pfizer·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Rheumatoid Arthritis
Drug/Device/Intervention: tofacitinib
Study type: Observational
Intervention type: drug

Sponsor & location

Primary sponsor: Pfizer

Timeline & enrollment

Phase: N/A
Start date: May 15, 2024
End date: Jul 15, 2024
Enrollment: 20000 participants

Primary outcome

Percentage of Participants With Clinical Disease Activity Index (CDAI) =10.0

Summary

The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling.  The study will look at data from a large, US-based group of RA patients who have taken the below medicines:  - Tofacitinib  - Abatacept  - Tocilizumab or sarilumab  The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.

ICD-10 classifications

Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06418529
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06418529 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer and is currently Not yet recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 20000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.